BiochemiaUrody - Strona Barbary Kwiatkowskiej (TYLKO-DO-ODCZYTU)

BasiaKwiatkowska

Basia
Site Admin

Dołączył: 18 Mar 2005
Posty: 1710
:

Items
Wysłany: 19 Mar 2005 11:21 am Temat postu: Estrogeny

--------------------------------------------------------------------------------

Watki skopiowane z tego postu:
[link widoczny dla zalogowanych]

"Wspomnialas o estrogenach do zewnetrznego stosowania. Jakiego rodzaju preparaty
mialas na mysli? Takie na twarz? Co konkretnie zawieraja? I czy w Stanach mozan
je kupic bez recepty? Bardzo jestem ciekawa o jaki typ specyfikow chodzi ..."
----------------------
Tak chodzi o kremy zawierajace estrogeny, w Polsce trzeba by trafic na
ginekologa co wie troche wiecej, do ktorego mamy zaufanie i ktory zechcialby
przepisac recepte na krem z estrogenami robiony w aptece, ginekolog musi jednak
miec wiedze jakie stezenie i typ, a osoba stosujaca musi tez wiedziec jak to
stosowac by sobie nie zaszkodzic, musi byc pewna ze nie ma przeciwwskazan
medycznych, np przebyty rak piersi czy drog rodnych, albo zwiekszone ryzyko
raka w rodzinie. Wspominala o tym kiedys Maria Noszczyk w jakims swoim artykule
czy wypowiedzi, ze sama takze ekperymentowala. W Stanach mozna kupic takie
preparaty bez recepty ale tylko na internecie.
 Estrogens. As the population of postmenopausal women increases,
interest in the effects of estrogen grows. Estrogen appears to aid in the
prevention of skin aging in several ways:
o it prevents a decrease in skin collagen in postmenopausal women;
topical and systemic estrogen therapy can increase the skin collagen content
and therefore maintain skin thickness.
o it maintains skin moisture by increasing acid mucopolysaccharides and
hyaluronic acid in the skin and possibly maintaining stratum corneum barrier
function.
o Sebum levels are higher in postmenopausal women receiving hormone
replacement therapy.
o wrinkling also may benefit from estrogen as a result of the effects of
the hormone on the elastic fibers and collagen.
o estrogen promotes wound healing by regulating the levels of a cytokine.
Topical estrogen has been found to accelerate and improve wound healing in
elderly men and women.
The mechanisms of how estrogens exert their actions, particularly in non-
reproductive tissues such as the skin are still not well understood, although
estrogens have significant effects on many aspects of skin physiology including
the epidermis, dermis, vasculature, hair follicle and the sebaceous, eccrine
and apocrine glands, skin aging, pigmentation, hair growth, sebum production
and skin cancer.
The major reported effects of estrogens are as regulators of connective tissue
molecules, namely collagen and hyaluronic acid. Reaserchers investigated the
regulation of connective tissue synthesis by topical estrogens in a hairless
mouse model of photodamaged skin and found that 17beta-estradiol (17beta-E) and
17alpha-estradiol (17alpha-E), were as effective as all- trans-retinoic acid in
stimulating the development of new connective repair zones in photodamaged
skin. 17beta-E and 17alpha-E caused a skin thickening response in normal
hairless mouse skin after three daily treatments. Skin thickening is due to
water accumulation as a result of estrogen-induced hyaluronan synthesis.
Topical estrogens are important regulators of connective tissue synthesis in
photodamaged skin as well as normal skin. These findings are consistent with
reports from human studies in which estrogen has been found to stimulate
collagen production.
One study examined the soy isoflavones genistein (Gen) and daidzein (Dai) on
the production of hyaluronic acid (HA) in a transformed human keratinocyte
culture and in hairless mouse skin following topical application for 2 weeks.
Gen and Dai, but not their glycosides, significantly enhanced the production of
HA. Topical Gen and Dai may prevent and improve the cutaneous alterations
caused by the loss of HA in skin.
Researchers applied hyaluronidase, estriol, and base cream (as a control) to
separate animal groups for 5 weeks, and their effects were studied on tissue
expansion. Both hyaluronidase and estriol enhanced the rate of expansion when
compared with control animals. Estriol was more effective than hyaluronidase.
Recent use of hormone replacement therapy is required for optimum bone fracture
protection, but therapy can be started several years after the menopause. The
protective effect increases with duration of use, and an oestrogen-sparing
effect is achieved when progestins are included in the regimen.
Estriol has been found to provide some of the protection without the risks
associated with stronger estrogens. Estriol may exert either agonistic or
antagonistic effects on estrogen. Estriol's effect on cardiac risk factors has
also been somewhat equivocal; however, unlike conventional estrogen
prescriptions, it does not seem to contribute to hypertension. Although estriol
appears to be much safer than estrone or estradiol, its continuous use in high
doses may have a stimulatory effect on both breast and endometrial tissue. In
one study, 9 women were treated topically for three months with 0.01%
estradiol ointment and 8 were treated with 0.3% estriol ointment. Serum hormone
levels and the appearance of vaginal smears showed no significant change during
treatment.
The coincidence of symptoms and the onset of skin aging suggests that estrogen
deficiency may be a common and important factor in the perimenopausal woman.
Researchers investigated whether topical treatment of the skin with estrogen
could reverse some of the changes in the aging skin. The effects of 0.01%
estradiol and 0.3% estriol compounds were compared in 59 preclimacteric women
with skim aging symptoms. After treatment for 6 months, elasticity and firmness
of the skin had markedly improved and the wrinkle depth and pore sizes had
decreased by 61 to 100% in both groups. Skin moisture had increased and
significant, or even highly significant, decreases of wrinkle depth in the
estradiol and the estriol groups were observed, respectively. Significant
increases of Type III collagen labeling were combined with increased numbers of
collagen fibers at the end of the treatment period. No systemic hormonal side
effects were noted.
Local iontophoresis was performed with estriol--a mainly topically active
estrogen. Eighteen women were treated with estriol iontophoresis twice weekly
for a period of 3 months. Improvement of acne scars was observed in 100% of the
group treated with estriol iontophoresis. No hormonal changes were noted in the
estrogen group. Treatment was shown to be effective in decreasing acne scars
and persistence of effects. This promising new therapeutic approach may thus
replace invasive treatment methods in many patients.
The aging skin of the face of perimenopausal females was treated with a 0.3%
estriol cream (8 patients) or with a 0.01% estradiol cream (10 patients) for 6
months. Both treatment groups showed improvement of the various skin aging
symptoms at the end of treatment. The effects of the group treated with topical
estriol were slightly superior with regard to their extent and onset. No
hormonal side effects were noted either clinically or by hormone monitoring.
However, for minimizing the risk of systemic hormonal side effects,
concentrations and size of application field should be limited.
The effect of local oestriol treatment for three weeks on the abdominal skin
was studied in 14 postmenopausal women. Six control patients received a similar
ointment without oestriol. The elastic fibers in the papillary dermis were
thickened, better orientated and slightly increased in number in half of these
patients but in none of the control patients. The epidermal thickness was
slightly increased in four of the patients treated with oestriol. No
significant changes were observed in the epidermal cell size, mitotic activity,
dermal vascularization or inflammatory infiltrate between the specimens taken
before and after the treatment or between the treatment groups.
Skinfold thickness was measured in 130 post-menopausal women treated with long-
term hormone therapy. One group of 50 women took oestradiol valerate 2 mg/day
for 3 wk out of 7, a second group comprising 19 women received oestriol
succinate 2 mg/day and the remaining group of 61 women used oestradiol valerate
2 mg/day combined sequentially with norgestrel 0.5 mg/day. The skinfold
thickness in all the treated groups was significantly greater than that in the
controls.
The effect of three years estriol succinate therapy (2 mg/day) on the skin was
studied in 20 castrated women whose average age was 48 years. A control group
whose average age was also 48 years, consisted of 7 patients who did not
receive any treatment after castration. There was no significant reduction in
epidermal thickness during the three year course of estriol succinate therapy.
On the other hand the significant thinning of the epidermis in the control
group was observed three years after oophorectomy.
Researchers applied hyaluronidase, estriol, and base cream (as a control) to
separate animal groups for 5 weeks, and their effects were studied on tissue
expansion. Both hyaluronidase and estriol enhanced the rate of expansion when
compared with control animals. Estriol was more effective than hyaluronidase.
Recent use of hormone replacement therapy is required for optimum bone fracture
protection, but therapy can be started several years after the menopause. The
protective effect increases with duration of use, and an oestrogen-sparing
effect is achieved when progestins are included in the regimen.
Estriol has been found to provide some of the protection without the risks
associated with stronger estrogens. Estriol may exert either agonistic or
antagonistic effects on estrogen. Estriol's effect on cardiac risk factors has
also been somewhat equivocal; however, unlike conventional estrogen
prescriptions, it does not seem to contribute to hypertension. Although estriol
appears to be much safer than estrone or estradiol, its continuous use in high
doses may have a stimulatory effect on both breast and endometrial tissue. In
one study, 9 women were treated topically for three months with 0.01%
estradiol ointment and 8 were treated with 0.3% estriol ointment. Serum hormone
levels and the appearance of vaginal smears showed no significant change during
treatment.
The coincidence of symptoms and the onset of skin aging suggests that estrogen
deficiency may be a common and important factor in the perimenopausal woman.
Researchers investigated whether topical treatment of the skin with estrogen
could reverse some of the changes in the aging skin. The effects of 0.01%
estradiol and 0.3% estriol compounds were compared in 59 preclimacteric women
with skim aging symptoms. After treatment for 6 months, elasticity and firmness
of the skin had markedly improved and the wrinkle depth and pore sizes had
decreased by 61 to 100% in both groups. Skin moisture had increased and
significant, or even highly significant, decreases of wrinkle depth in the
estradiol and the estriol groups were observed, respectively. Significant
increases of Type III collagen labeling were combined with increased numbers of
collagen fibers at the end of the treatment period. No systemic hormonal side
effects were noted.
Local iontophoresis was performed with estriol--a mainly topically active
estrogen. Eighteen women were treated with estriol iontophoresis twice weekly
for a period of 3 months. Improvement of acne scars was observed in 100% of the
group treated with estriol iontophoresis. No hormonal changes were noted in the
estrogen group. Treatment was shown to be effective in decreasing acne scars
and persistence of effects. This promising new therapeutic approach may thus
replace invasive treatment methods in many patients.
The aging skin of the face of perimenopausal females was treated with a 0.3%
estriol cream (8 patients) or with a 0.01% estradiol cream (10 patients) for 6
months. Both treatment groups showed improvement of the various skin aging
symptoms at the end of treatment. The effects of the group treated with topical
estriol were slightly superior with regard to their extent and onset. No
hormonal side effects were noted either clinically or by hormone monitoring.
However, for minimizing the risk of systemic hormonal side effects,
concentrations and size of application field should be limited.
The effect of local oestriol treatment for three weeks on the abdominal skin
was studied in 14 postmenopausal women. Six control patients received a similar
ointment without oestriol. The elastic fibers in the papillary dermis were
thickened, better orientated and slightly increased in number in half of these
patients but in none of the control patients. The epidermal thickness was
slightly increased in four of the patients treated with oestriol. No
significant changes were observed in the epidermal cell size, mitotic activity,
dermal vascularization or inflammatory infiltrate between the specimens taken
before and after the treatment or between the treatment groups.
Skinfold thickness was measured in 130 post-menopausal women treated with long-
term hormone therapy. One group of 50 women took oestradiol valerate 2 mg/day
for 3 wk out of 7, a second group comprising 19 women received oestriol
succinate 2 mg/day and the remaining group of 61 women used oestradiol valerate
2 mg/day combined sequentially with norgestrel 0.5 mg/day. The skinfold
thickness in all the treated groups was significantly greater than that in the
controls.
The effect of three years estriol succinate therapy (2 mg/day) on the skin was
studied in 20 castrated women whose average age was 48 years. A control group
whose average age was also 48 years, consisted of 7 patients who did not
receive any treatment after castration. There was no significant reduction in
epidermal thickness during the three year course of estriol succinate therapy.
On the other hand the significant thinning of the epidermis in the control
group was observed three years after oophorectomy.
Researchers found that estriol penetrates considerably slower and is less able
to enter the dermis than the estradiols. Estriol reaches the dermis only in low
concentrations. 17 alpha-estriol which has only weak sexhormone properties in
humans penetrates as well as the sexhormone 17 beta-estradiol.
The ability of estrogens to protect against DNA damage induced by either
hydrogen peroxide or arachidonic acid alone or in combination with Cu2+ was
investigated. Estradiol-17 beta significantly decreased the formation of single
and double strand breaks in DNA induced by H2O2 alone or with Cu2+. Equilin (an
equine estrogen) was more effective than estradiol-17 beta at the doses tested.
Arachidonic acid in the presence of Cu2+ caused the formation of high levels of
linear DNA which was protected by estrogen with equilen being more effective.
zrodlo Biochemistry of Beauty

Ostatnio zmieniony przez Basia dnia 31 Sie 2005 04:59 pm, w całości zmieniany 1 raz

Powrót do góry

Basia
Site Admin

Dołączył: 18 Mar 2005
Posty: 1710
:

Items
Wysłany: 19 Mar 2005 11:22 am Temat postu:

--------------------------------------------------------------------------------

Exp Dermatol. 2004;13 Suppl 4:36-40.

Skin aging and . hormones in women -- clinical perspectives for intervention
by hormone replacement therapy.

Sator PG, Schmidt JB, Rabe T, Zouboulis CC.

Department of Dermatology, Municipal Hospital Lainz, Vienna, Austria.
[link widoczny dla zalogowanych]

The skin, the largest organ of the body, is the organ in which changes
associated with aging are most visible. The skin is a target organ for various
hormones, and . steroids have a profound influence on the aging process. A
decrease in . steroids thus induces a reduction of those skin functions that
are under hormonal control. Keratinocytes, Langerhans' cells, melanocytes,
sebaceous glands, collagen content and the synthesis of hyaluronic acid, for
example, are under hormonal influence. Topical application of estrogens has a
positive effect on skin aging parameters, whilst numerous studies have also
shown the positive influence of systemic hormone replacement therapy on skin
aging. As an alternative treatment, phytohormones may be administered, with the
structural similarity to 17beta-estradiol explaining their estrogen-like
effects. However, isoflavonoids exhibit an inferior biological potency to
synthetic estrogens. Although a large number of publications have documented
the effects of . hormones on the aging process, it is obvious that hormone
replacement should not be administered as an independent treatment for skin
aging.

PMID: 15507111 [PubMed - in process]

Arch Dermatol Res. 2002 Jul;294(5):231-6. Epub 2002 Jun 07.

Topical estrogens: their effects on connective tissue synthesis in hairless
mouse skin.

Gendimenico GJ, Mack VJ, Siock PA, Mezick JA.

Current address: Johnson & Johnson Pharmaceutical Research & Development,
L.L.C., US Route 202, PO Box 300, Raritan, NJ 08869-0602, USA.
[link widoczny dla zalogowanych]

Skin is an important target organ for estrogens. The major reported effects of
estrogens are as regulators of connective tissue molecules, namely collagen and
hyaluronic acid. We investigated the regulation of connective tissue synthesis
by topical estrogens in a hairless mouse model of photodamaged skin, which has
been previously shown to respond to topical retinoids. The naturally occurring
estrogen, 17beta-estradiol (17beta-E) and a close stereoisomer, 17alpha-
estradiol (17alpha-E), were found to be as effective as all- trans-retinoic
acid in stimulating the development of new connective repair zones in
photodamaged skin. Furthermore, 17beta-E and 17alpha-E caused a skin thickening
response in normal hairless mouse skin after three daily treatments. Skin
thickening is due to water accumulation as a result of estrogen-induced
hyaluronan synthesis. Our results show that topical estrogens are important
regulators of connective tissue synthesis in photodamaged skin as well as
normal skin. These findings are consistent with reports from human studies in
which estrogen has been found to stimulate collagen production. We also
demonstrated that 17alpha-E, previously thought to be a weak or inactive
estrogen, is less potent than 17beta-E, but nonetheless topically effective in
stimulating connective tissue synthesis.

PMID: 12115026 [PubMed - indexed for MEDLINE]

Am J Clin Dermatol. 2001;2(3):143-50.

Estrogen and skin. An overview.

Shah MG, Maibach HI.

University of California, San Francisco, School of Medicine, San Francisco,
California, USA. [link widoczny dla zalogowanych]

As the population of postmenopausal women increases, interest in the effects of
estrogen grows. The influence of estrogen on several body systems has been well-
documented; however, one area that has not been explored is the effects of
estrogen on skin. Estrogen appears to aid in the prevention of skin aging in
several ways. This reproductive hormone prevents a decrease in skin collagen in
postmenopausal women; topical and systemic estrogen therapy can increase the
skin collagen content and therefore maintain skin thickness. In addition,
estrogen maintains skin moisture by increasing acid mucopolysaccharides and
hyaluronic acid in the skin and possibly maintaining stratum corneum barrier
function. Sebum levels are higher in postmenopausal women receiving hormone
replacement therapy. Skin wrinkling also may benefit from estrogen as a result
of the effects of the hormone on the elastic fibers and collagen. Outside of
its influence on skin aging, it has been suggested that estrogen increases
cutaneous wound healing by regulating the levels of a cytokine. In fact,
topical estrogen has been found to accelerate and improve wound healing in
elderly men and women. The role of estrogen in scarring is unclear but recent
studies indicate that the lack of estrogen or the addition of tamoxifen may
improve the quality of scarring. Unlike skin aging, the role of endogenous and
exogenous estrogen in melanoma has not been well established.

Publication Types:

* Review
* Review, Tutorial

PMID: 11705091 [PubMed - indexed for MEDLINE]

Int J Dermatol. 1996 Sep;35(9):669-74.

Treatment of skin aging with topical estrogens.

Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A.

Department of Dermatology, University of Vienna Medical School, Austria.

BACKGROUND. The coincidence of climacteric symptoms and the beginning of skin
aging suggests that estrogen deficiency may be a common and important factor in
the perimenopausal woman. Often hormones have been considered important in
endogenous aging of the skin, but their role has not been clearly defined.
Therefore, we investigated, whether topical treatment of the skin with estrogen
could reverse some of the changes in the aging skin. MATERIAL AND METHODS. The
effects of 0.01% estradiol and 0.3% estriol compounds were compared in 59
preclimacteric women with skim aging symptoms. Monthly determinations of
estrodiol (E2), follicle-stimulating hormone (FSH), and prolactin (PRL) were
done and the monthly clinical monitoring was supplemented by measurements of
skin hydration by corneometry and profilometry. In 10 patients, skin biopsies
were taken for immunohistochemical determination of collagen types I and III.
RESULTS. After treatment for 6 months, elasticity and firmness of the skin had
markedly improved and the wrinkle depth and pore sizes had decreased by 61 to
100% in both groups. Furthermore, skin moisture had increased and the
measurement of wrinkles using skin profilometry, revealed significant, or even
highly significant, decreases of wrinkle depth in the estradiol and the estriol
groups, respectively. On immunohistochemistry, significant increases of Type
III collagen labeling were combined with increased numbers of collagen fibers
at the end of the treatment period. As to hormone levels, only those of PRL had
increased significantly and no systemic hormonal side effects were noted.

Publication Types:

* Clinical Trial
* Controlled Clinical Trial

PMID: 8876303 [PubMed - indexed for MEDLINE]
Treatment of skin ageing symptoms in perimenopausal females with estrogen
compounds. A pilot study.

Schmidt JB, Binder M, Macheiner W, Kainz C, Gitsch G, Bieglmayer C.

Department of Special and Environmental Dermatology, University of Vienna
Medical School, Wien, Austria.

A wide range of somatic symptoms of the perimenopausal female is due to the
decrease of estrogen at that age. Minor attention has been paid hitherto to the
involvement of estrogens in female skin ageing symptoms. In our study, the
ageing skin of the face of perimenopausal females was treated with a 0.3%
estriol cream (8 patients) or with a 0.01% estradiol cream (10 patients) for 6
months. Dermatologic follow-up was performed monthly. At each follow-up venous
blood for radioimmuno assay determination of prolactin (PRL), follicle
stimulating hormone (FSH) and estradiol (E2) was sampled. In addition, prior to
and after 3 and 6 months of treatment, gynecological examinations for
climacteric symptoms, mammary and colposcopic investigations and vaginal smears
for cytology were performed. Both treatment groups showed improvement of the
various skin ageing symptoms at the end of treatment. The effects of the group
treated with topical estriol were slightly superior with regard to their extent
and onset. No hormonal side effects were noted either clinically or by hormone
monitoring. According to these preliminary results, local estrogen treatment
appears to be a promising new approach for the treatment of skin ageing in
perimenopausal females. However, for minimizing the risk of systemic hormonal
side effects, concentrations and size of application field should be limited.

PMID: 7877517 [PubMed - indexed for MEDLINE]

Maturitas. 1987 Apr;9(1):1-5.

Skin collagen changes in post-menopausal women receiving oestradiol gel.

Brincat M, Versi E, O'Dowd T, Moniz CF, Magos A, Kabalan S, Studd JW.

Sixteen post-menopausal women who had never previously received any hormonal
treatment applied Oestrogel cream 1.5 mg/day percutaneously for 1 yr. Skin
biopsies were taken from the abdomen and from the lateral aspect of the thigh
at 0, 3, 6 and 12 mth, and the changes in skin collagen content were noted. The
abdominal skin collagen content increased significantly (P less than 0.001)
over the 1-yr treatment period. The thigh skin collagen content also increased,
but did not reach significant levels. There was a strong correlation between
the change in skin collagen content (in both the abdomen and the thigh) and the
original skin collagen content, indicating that the change in collagen content
in response to oestrogen therapy is dependent on the original level. There is
no further increase once an 'optimum' skin collagen level has been reached.

PMID: 3600420 [PubMed - indexed for MEDLINE]

Maturitas. 1989 Dec;11(4):295-304.

Skin changes in menopause.

Bolognia JL, Braverman IM, Rousseau ME, Sarrel PM.

Department of Dermatology, Yale University School of Medicine, New Haven,
Connecticut.

Skin signs and symptoms were examined in 46 menopausal women prior to estrogen
replacement therapy. Several symptoms such as pruritus, bruising, dryness and
thinning were seen more frequently in sun-exposed skin emphasizing the
contribution of photoaging. At the end of a 6-mth treatment period, no
significant difference was observed in the prevalence or severity of the
cutaneous signs and symptoms when patients receiving transdermal 17 beta-
estradiol (Estraderm) were compared with controls (the only exception was
cutaneous flushing). Elastic fibers from sun-protected (buttock) skin of
menopausal women were studied by light and electron microscopy. In 3 women
(ages 30-37) with a history of premature menopause, the elastic fibers had
several degenerative changes including coalescence of cystic spaces into
lacunae, peripheral fragmentation, granular degeneration and splitting of the
fibers into strands. Similar age-related ultrastructural changes are normally
found in individuals that are at least 20 yrs older than these patients. These
findings are suggestive of a relationship between premature aging of the dermal
elastic fibers and estrogen deprivation.

Publication Types:

* Clinical Trial
* Controlled Clinical Trial

PMID: 2693917 [PubMed - indexed for MEDLINE]

Therapie. 1996 Jan-Feb;51(1):67-70.

[Hormone replacement treatment and skin aging]

[Article in French]

Vaillant L, Callens A.

Service de Dermatologie, CHU Tours, France.

Ageing of the skin results from the synergistic effects of intrinsic ageing
(due to age and genetic factors), photoageing (due to ultraviolet radiation)
and, for women, hormonal ageing (due to oestrogen deficiency in postmenopausal
women). Oestrogens receptors and metabolism or inactivation of oestradiol have
been demonstrated in the skin, and the pilosebaceous unit is a target for
sexual steroids. Could hormonal replacement therapy (HRT) be a treatment for
the symptoms of skin ageing (dryness, roughness, burning and atrophy of the
skin, itching, cold intolerance, wrinkles, hyperpilosity, alopecia)? In some
experimental studies oestrogens increase the activity of fibroblasts and water,
hyaluronic acid and collagen dermal contents. Some studies have demonstrated
that oestrogen treatment increases skin thickness, mitotic activity of
keratinocytes, and dermal collagen content in postmenopausal women. Thus HRT
could theoretically treat skin ageing. It has been shown that HRT alleviates
some symptoms of skin ageing (dryness of hair and skin) and that flushes
disappear. We demonstrated that non-invasive measurements of physical
parameters of the skin can reveal increase in skin thickness (+10 to +20 per
cent) in women treated by HRT vs non treated, especially in the application
area of oestrogen and in the non-sun-exposed areas. In our study HRT alleviated
the hyposeborrhoea usually seen after menopause and could contribute to the
amelioration of some complaints of post menopausal women such as roughness or
dehydrated skin. Hormonal ageing is quantitatively less than actinic ageing,
but its treatment is easier. Moreover HRT increases skin thickness,
contributing to the prevention of atrophy (with fragile and fading skin) due to
intrinsic ageing, and it limits the masculinization of facial hair and skin
experienced by women as a sign of ageing. In conclusion HRT treats oestrogen
deficiency and can be used to treat skin ageing.

Publication Types:

* Review
* Review, Tutorial

PMID: 8762222 [PubMed - indexed for MEDLINE]

Powrót do góry

Basia
Site Admin

Dołączył: 18 Mar 2005
Posty: 1710
:

Items
Wysłany: 19 Mar 2005 11:25 am Temat postu:

--------------------------------------------------------------------------------

Zamiast etrogenow mozna sprobowac izoflavony sojowe, ktore maja podobne
dzialanie, ale slabsze.
-----------------------------------

W sprawie tematu tego watku dostalam list:

Cytat:
Basiu, wstrzeliłam się ze swoim pytaniem w wątek na forum GW, lecz pewnie pozostanie tam niezuważony. Toteż pozwoliłam sobie napisać do Ciebie Bezpośrednio.
Czy masz jakieś typy kosmetyków ze wspomnianymi izoflawonami w składzie dostępne na polskim rynku? Czy kremy z estradiolem stosowane w ginekologii można używać na twarz. Bardzo chciałabym przeciwdziałam siłom grawitacji odznaczającym się już na mojej twarzy, ale cerę mam bardzo mocno wrażliwą i alergiczną i, niestety retinoidy odpadają. A już płakać mi się chce jak patrzę w lustro.
Ucieszyłam się bardzo, gdy zorientowałam się, że znów jesteś obecna na forum.
Pozdrawiam Cię bardzo ciepło.

--------------------------------------------------------------------------------

Skopiowalam w tym watku wypowiedzi z forum Uroda dotyczace estrogenow, byla tu takze mowa o kremach z estrogenami stosowanymi w ginekologii:
"Wspomnialas o estrogenach do zewnetrznego stosowania. Jakiego rodzaju preparaty
mialas na mysli? Takie na twarz? Co konkretnie zawieraja? I czy w Stanach mozan
je kupic bez recepty? Bardzo jestem ciekawa o jaki typ specyfikow chodzi ..."
----------------------
Tak chodzi o kremy zawierajace estrogeny, w Polsce trzeba by trafic na
ginekologa co wie troche wiecej, do ktorego mamy zaufanie i ktory zechcialby
przepisac recepte na krem z estrogenami robiony w aptece, ginekolog musi jednak
miec wiedze jakie stezenie i typ, a osoba stosujaca musi tez wiedziec jak to
stosowac by sobie nie zaszkodzic, musi byc pewna ze nie ma przeciwwskazan
medycznych, np przebyty rak piersi czy drog rodnych, albo zwiekszone ryzyko
raka w rodzinie. Wspominala o tym kiedys Maria Noszczyk w jakims swoim artykule
czy wypowiedzi, ze sama takze ekperymentowala. W Stanach mozna kupic takie
preparaty bez recepty ale tylko na internecie.

Jesli chodzi o kosmetyki dostepne na polskim rynku zawierajace izoflawony sojowe to robie wlasnie poszukiwania. Poniewaz nie mam bezposredniego dostepu do kosmetykow w Polsce i ich skladow z Wasza pomoca mozemy zrobic liste produktow wartych uwagi, ktore mozna kupic w Polsce.
Zaloze osobny watek z propozycjami takich kremow.
Pozdrawiam

Cytat:
Basiu, prosiłabym Cię bardzo o opinię, czy krem o takim składzie może być stosowany na twarz?
1g kremu zawiera: substancję czynną estriol 1mg oraz substancje pomocnicze:Eutanol G, syntetyczny olbrot,glicerol,alkohol cetylowy, alkohol stearylowy, polisorbat 60,monostearynian sorbitanu, kwas mlekowy, chlorowodorek chlorheksydyny,wodorotlenek sodu, woda oczyszczona.
Jeśli tak, to może go z czymś mieszać?
Pozdrawiam Cię ciepło z jeszcze zimowej Polski.
3/15/2005, 14:10 Send Email to jollyz

Krem zawiera 0,1% estriolu, mozna go stosowac na twarz, nie trzeba z niczym mieszac, bo wtedy tylko go rozcienczysz. Jesli jestes w granicy ponizej 35 lat to raczej nei zobaczysz duzych efektow, poza wplywm na gojenie sie blizn, sladow po wypryskach.

Ostatnio zmieniony przez Basia dnia 31 Sie 2005 04:58 pm, w całości zmieniany 1 raz

Powrót do góry

ewunia74

Dołączył: 30 Kwi 2005
Posty: 74
:
Skąd: sztokholm

Items
Wysłany: 27 Cze 2005 11:24 am Temat postu:

--------------------------------------------------------------------------------

a mozesz zdradzic jaki to krem,jakiej firmy?

Powrót do góry

jollyz

Dołączył: 25 Mar 2005
Posty: 26
:

Items
Wysłany: 29 Cze 2005 01:31 am Temat postu:

--------------------------------------------------------------------------------

O ile dobrze pamiętam, jego nazwa to Ovestin(??). Jest to krem stosowany w ginekologii.

Powrót do góry

Basia
Site Admin

Dołączył: 18 Mar 2005
Posty: 1710
:

Items
Wysłany: 20 Lip 2005 03:31 pm Temat postu:

--------------------------------------------------------------------------------

Basia napisał:
nan napisał:
Dziękuję Basiu. Ostatnio przetoczyła się po Wizażu mała bitwa między zwolenniczkami opalania ("bo moja mama opala się od wczesnej młodości i wygląda na 10 lat mniej niż ma") a zwolenniczkami filtrów i nie leżenia plackiem.

Przy okazji zaczęłam się zastanawiać nad tym wszystkim i czy np. fakt, że mama opala się od... i tak dalej i przebarwień i zmarszczek nie ma nie może być przypadkiem związane z tym, że jeszcze nie przeszła menopauzy? Przecież hormony mają ogromy wpływ nie tylko na zdrowie i samopoczucie, ale także na wygląd skóry, włosów. Moja mama też jest opalaczką i faktycznie przebarwień raczej nie ma (lub są mało widoczne), ale za to popękane naczynka krwionośne i zmarchy też ma, owszem (ale przy okazji również 58 lat i menopauzę już przeszła). Jak to jest Basiu?

To prawda, po menopauzie kobiety zaczynaja sie bardzo szybko zmieniac i starzec, terapia hormonalna jest wtedy bardzo pomocna.

Powrót do góry

Basia
Site Admin

Dołączył: 18 Mar 2005
Posty: 1710
:

Items
Wysłany: 11 Sie 2005 05:08 pm Temat postu:

--------------------------------------------------------------------------------

ewunia74 napisał:
a mozesz zdradzic jaki to krem,jakiej firmy?

Ewa, mam nadzieje, ze nie interesujesz sie tym kremem z mysla o sobie!!!

Powrót do góry

nastazja2

Dołączył: 04 Maj 2005
Posty: 3
:
Skąd: Kraków

Items
Wysłany: 12 Sie 2005 10:53 am Temat postu:

--------------------------------------------------------------------------------

jollyz napisał:
O ile dobrze pamiętam, jego nazwa to Ovestin(??). Jest to krem stosowany w ginekologii.

Czy ktoś już stosowal ten krem . Mam straszna ochote sprobowac ... ale sie boje

Powrót do góry

Basia
Site Admin

Dołączył: 18 Mar 2005
Posty: 1710
:

Items
Wysłany: 12 Sie 2005 11:09 am Temat postu:

--------------------------------------------------------------------------------

nastazja2 napisał:
jollyz napisał:
O ile dobrze pamiętam, jego nazwa to Ovestin(??). Jest to krem stosowany w ginekologii.

Czy ktoś już stosowal ten krem . Mam straszna ochote sprobowac ... ale sie boje

Ile masz lat? Wkroczylas juz w okres menopauzy, jestes na HTZ?

Powrót do góry

nastazja2

Dołączył: 04 Maj 2005
Posty: 3
:
Skąd: Kraków

Items
Wysłany: 27 Sie 2005 11:39 pm Temat postu:

--------------------------------------------------------------------------------

39 i 2 mies